Table 2:
Bivariate Analysis of Independent Variables and Outcome: Guideline Concordant Care Received
| GCC Received (n) | Not Received (n) | p-value | |
|---|---|---|---|
| Total | 65 | 115 | |
| Sex | .90 | ||
| Male | 35 | 63 | |
| Female | 30 | 52 | |
| Insurance (primary) | .02* | ||
| Non-commercial | 31 | 76 | |
| Commercial | 34 | 39 | |
| Age group: young vs. old >12y | .03* | ||
| 0–11Y | 19 | 53 | |
| 12Y < 26Y | 46 | 62 | |
| Race | .01** | ||
| White | 31 | 79 | |
| Non-White | 34 | 36 | |
| Ethnicity | .50 | ||
| Non-Hispanic | 39 | 75 | |
| Hispanic | 26 | 40 | |
| Location | .20 | ||
| Inpatient | 44 | 88 | |
| Outpatient | 21 | 27 | |
| Provider setting | <.0001* | ||
| Pediatric Oncology | 29 | 103 | |
| Adult Oncology | 36 | 12 | |
| Emetogenicity | .33 | ||
| Highly-emetogenic (HEC) | 43 | 84 | |
| Moderately-emetogenic (MEC) | 22 | 31 | |
| Chemotherapy type | <.001* | ||
| Cisplatin based therapy | 21 | 13 | |
| Non-Cisplatin based therapy | 44 | 102 | |
| Cancer type: solid vs. not | .007* | ||
| Solid tumor | 35 | 38 | |
| All others | 30 | 77 | |
| Cancer status | .91 | ||
| First occurrence | 10 | 17 | |
| Relapse | 55 | 98 |
*
Significant at the 5% level, included in multivariable logistic regression
**
Excluded from multivariable regression due to 14% “unknown” status